Get in Touch

AIM Biotech Launches Organ-on-a-Chip Contract Research Service

March 2, 2021 — Singapore & Boston, MA — AIM Biotech has launched a contract research service, which uses its organ-on-a-chip technology to accelerate and improve drug discovery and development. AIM’s 3D microfluidic organ-on-a-chip platform more accurately mimics the human microenvironment than conventional assays. As a result, drug discovery organizations can generate more predictive data and better inform their decisions ahead of clinical trials.

The new service frees up resources for companies to evaluate compounds in three-dimensional human organ structures and interactions. AIM can collaborate with partners to build specific protocols using AIM’s chips or perform work on validated protocols, which include applications in immunotherapy, T-cell therapy, vascular functions, neurobiology, and various aspects of cell biology. The service also offers companies an opportunity to evaluate the benefit of AIM’s organ-on-a-chip platform before bringing the technology in-house.

“Our new offering will help drug researchers worldwide get better pre-clinical results while also streamlining their workflow,” said Jim McGorry, CEO. “Companies are losing an extraordinary amount of time and money with clinical trial failures. The probability of success can be improved through organ-on-a-chip technology that offers human insight ahead of clinical trials.”

AIM’s new offering will be through a joint service lab at A*STAR’s Institute of Molecular and Cell Biology (IMCB) in Singapore. Prof. Hong Wanjin, IMCB executive director, commented, “Our collaboration with AIM Biotech expands our research capabilities in the growing field of organ-on-a-chip models. Together we look to bring these services to biopharmaceutical companies and researchers around the world.”

“This is an efficient and promising technology for mimicking the human tumor microenvironment. IMCB will be a pivotal partner to AIM Biotech and bring key scientific expertise to ensure competitive and high-quality data production,said Dr. Andrea Pavesi, a consultant to AIM as well as an investigator at IMCB, and who was instrumental in establishing the joint lab. “It’s clear this technology is already playing a pivotal role in identifying the next-generation of biomarkers and therapies.”




AIM gives researchers 3D human biology-on-a-chip to revolutionize their preclinical drug discovery and molecular research. At its core is the AIM Chip, a specialized 3D microfluidics device that makes it easy to generate relevant human data from disease-specific assays. Researchers are able to create their own assays or apply validated protocols, which include angiogenesis, vasculogenesis, metastasis, immuno-oncology, and 3D culture of tumor samples. AIM Biotech is located in Singapore and Boston, MA.

Key Takeaways
  • Drug discovery companies can free up resources to take advantage of AIM’s organ-on-a-chip technology at a joint service laboratory with the Agency for Science, Technology and Research (A*STAR)’s Institute of Molecular and Cell Biology (IMCB) in Singapore.
  • The AIM organ-on-a-chip platform generates more predictive human data for drug discovery & development.
  • Validated applications include cancer and immunotherapy, vascular functions, neurobiology and various aspects of cell biology.
Media Gallery
Files
Quotes
Companies are losing an extraordinary amount of time and money with clinical trial failures. The probability of success can be improved through org...
Jim McGorryCEO
Our collaboration with AIM Biotech expands our research capabilities in the growing field of organ-on-a-chip models. Together we look to bring thes...
Prof. Hong WanjinIMCB Executive Director
Related Bios
Jim McGorry
Chief Executive Officer
View Full Bio>>
Wanjin Hong
IMCB EXECUTIVE DIRECTOR
View Full Bio>>
Contacts
Media & Investors
aimbiotech@reportablenews.com